Physician profile
Atif M George
NPI 1124018627
$8,145.82
in general payments reported to CMS, 2019-2025
14 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,046 · 2020: $882 · 2021: $1,254 · 2022: $708 · 2023: $498 · 2024: $268 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,514.97 | 2019-2025 | Breztri, Airsupra |
| Amgen INC. | $1,206.12 | 2019-2024 | Repatha |
| Lilly USA, LLC | $1,023.48 | 2019-2023 | Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $841.92 | 2019-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $746.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $738.80 | 2019-2025 | Jardiance |
| Gilead Sciences, INC. | $241.51 | 2019-2020 | |
| Indivior INC. | $182.89 | 2019 | |
| Pfizer INC. | $166.19 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.34 | 2021 | |
| Merck Sharp & Dohme LLC | $106.40 | 2019 | |
| Orexo US, INC. | $89.27 | 2019 | |
| Vanda Pharmaceuticals INC. | $86.29 | 2020 | |
| Janssen Pharmaceuticals, INC | $78.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atif George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.